Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells
Author:
Funder
Korea Government
National R&D Program for Cancer Control, Ministry of Health & Welfare, Korea
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference42 articles.
1. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011
2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012
3. The quest to overcome resistance to EGFR-targeted therapies in cancer;Chong;Nat. Med.,2013
4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;Kobayashi;N. Engl. J. Med.,2005
5. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing;Gerlinger;N. Engl. J. Med.,2012
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Roles of IL-4, IL-13, and Their Receptors in Lung Cancer;Journal of Interferon & Cytokine Research;2024-09-01
2. Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands;Journal of Nanobiotechnology;2024-05-17
3. Targeting Antheraea pernyi silk fibroin modified dual-gene coexpressing vector enhances gene transport and promotes lung tumor suppression;International Journal of Biological Macromolecules;2024-03
4. IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis;Theranostics;2024
5. Transcriptome and Metabolome Analyses Reveal the Mechanism of Corpus Luteum Cyst Formation in Pigs;Genes;2023-09-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3